Development of a murine tumor-infiltrating lymphocyte therapy model for cholangiocarcinoma.

J Immunol · 2026 · PMC12704411 · PMID 40972018

Europe PMC DOI

hedged sentence

0.1200

closest p · 2.4× alpha

0.1200

boldest claim

The sentences

did not reach statistical significanceP = 0.12not close (p > 0.1)

Median survival in this group reached 60 days, compared to 53 days for CD3 TILs plus anti–PD-L1 or anti–PD-L1 alone, although this trend did not reach statistical significance ( P = 0.12; Fig. 5K ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.